Chief Executive Officer

PhD Medical Researcher and Chief Executive Officer

Regenetek Research Inc.

Education

PhD

PhD On

Doug Broeska, president of The CliniCard Inc, said in a statement that "Mobile commerce through NFC is already here through the growing availability of NFC-ready personal handsets looking for plug in uses.

The few Canadian attendees included Doug Broeska, CEO of CliniCard Research Inc., who as part of a doctoral study is currently participating in collecting data on MS patients who have undergone a combination of neck venoplasty and stem cell transplantation at CCSVI Clinic.

WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts.
The company has so far specifically focused their new technology on a number of autologous therapeutic stem cell trials for a range of neurologic diseases that are taking place in multiple centers worldwide.
Such software would have important application where limited financial resources are combined with the need to validate efficacy and prove reproducibility of therapy protocols.

"The ability to rigorously evaluate individual patients, monitor adverse events, and aggregate data from different patients in different centers while maintaining ethical standards will achieve better control of bias, generate greater statistical power, and produce more meaningful conclusions for clinical outcomes," says Dr. Broeska, CEO of Regenetek Research.
Indeed, for cases where every patient's cells are unique, randomized controlled trials are simply not possible as an appropriate design for clinical investigation.

"This is just getting back to the basics of medical research.
A lot of medical investigation used to be done this way," says Broeska.
"Many medical breakthroughs were made only through observations with an N of one, but now we have the advantage of being able to handle big data through new technologies.
We can chart the outcomes of many individual patient case studies over time, aggregate, and even compare the data in a meaningful way to produce valid evidence.
We are not limited to therapeutic stem cell research but that is an obvious place to start.
Moving all medical investigation forward, faster is our goal."

Inquiries may be directed to Dr. Doug Broeska at "info@regenetek.com" or call 204-975-9665.

Doug Broeska is a PhD Medical Researcher and CEO of Regenetek Inc, a Canadian Biotech Research firm working with several hospitals and clinics world-wide to develop medical procedural protocols for neurodegenerative disease management.